Skip to content
Adjuvance Technologies

Adjuvance Technologies

Empowering health.

  • About Us
  • Our Technology
  • Our Leadership
    • Board of Directors
    • Management Team
  • Investors & Media
  • Contact

JACS: Design and synthesis of potent Quillaja saponin vaccine adjuvants.

By jgardnerFebruary 17, 2010Publications
JACS: Design and synthesis of potent Quillaja saponin vaccine adjuvants.

Jacs_design_nihms172184

Jacs_design_nihms172184

Post navigation

Preclinical Evaluation of the Synthetic Adjuvant SQS-21 and its Constituent Isomeric Saponins

Recent Posts

  • ADJUVANCE PRESENTS ITS 2021 POTENTIAL AND PLANS AT THE BIOTECH SHOWCASE
  • ADJUVANCE TECHNOLOGIES ANNOUNCES NIH FUNDING FOR COVID-19 VACCINE RESEARCH
  • ADJUVANCE TECHNOLOGIES ANNOUNCES $20 MILLION SERIES A INVESTMENT FROM MORNINGSIDE VENTURE INVESTMENTS
  • Comparative preclinical evaluation of AS01 versus other Adjuvant systems in a candidate herpes zoster glycoprotein E subunit vaccine
  • NEJM Reports Efficacy of QS-21 Containing Herpes Zoster Subunit Vaccine
Copyright © All rights reserved. Theme Businessbiz by Sensational Theme